Today's Information |
Provided by: Qisda Corporation | |||||
SEQ_NO | 1 | Date of announcement | 2022/05/20 | Time of announcement | 16:21:55 |
Subject | The Company participates in TCI GENE INC.'s private placement of common shares | ||||
Date of events | 2022/05/20 | To which item it meets | paragraph 20 | ||
Statement | 1.Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield, etc.): TCI GENE INC.'s common shares in a private placement 2.Date of occurrence of the event:2022/05/20 3.Amount, unit price, and total monetary amount of the transaction: Qisda Corporation Number of Shares: 4,720,000 shares Price per Share: NTD$ 115.5 Amount: NTD$ 545,160,000 4.Trading counterparty and its relationship with the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed): TCI GENE INC. is not the Company's related party. 5.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary amount of transfer: NA 6.Where an owner of the underlying assets within the past five years has been a related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship with the Company at the time of the transaction: NA 7.Matters related to the current disposal of creditors' rights (including types of collaterals of the disposed creditor's rights; if creditor's rights over a related party, announcement shall be made of the name of the related party and the book amount of the creditor's rights, currently being disposed of, over such related party): NA 8.Profit or loss from the disposal (not applicable in cases of acquisition of securities) (those with deferral should provide a table explaining recognition): NA 9.Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important terms and conditions: Payment by wired 10.The manner of deciding on this transaction (such as invitation to tender, price comparison, or price negotiation), the reference basis for the decision on price, and the decision-making unit: decision-making department: Board Resolution Reference Price Basis: According to the price of TCI GENE INC.'s private placement of common shares and the reasonableness opinion issued by the CPA. The decision-making department: The Company's board of directors meeting. 11.Net worth per share of the Company's underlying securities acquired or disposed of:17.72 12.Cumulative no.of shares held (including the current transaction), their monetary amount, shareholding percentage, and status of any restriction of rights (e.g., pledges), as of the present moment: Qisda Corporation Number of Shares: 4,720,000 shares Amount: NTD$ 545,160,000 Percentage of Shareholding: around 17.84% Restriction on rights: Transferring shares has to follow relevant provisions regarding private placement in Securities and Exchange Act 13.Current ratio of securities investment (including the current trade, as listed in article 3 of Regulations Governing the Acquisition and Disposal of Assets by Public Companies) to the total assets and equity attributable to owners of the parent as shown in the most recent financial statement and working capital as shown in the most recent financial statement as of the present: Current ratio of long or short term securities investment (including the current trade approved by board of directors) to the total assets: 52.52% Current ratio of long or short term securities investment (including the current trade approved by board of directors) to the shareholder's equity: 141.67% Operating Capital: NTD$ -6,919,740 thousand. Source of funds:Self-owned capital purpose of the acquisition: In order to strengthen the company's biotechnology industry, it has stepped into the field of precision medicine. Through this investment, we will complement each other's resources, expand the biotechnology and medical care business, and provide customers with a wider range of products and services. 14.Broker and broker's fee:No 15.Concrete purpose or use of the acquisition or disposal: In order to strengthen the company's biotechnology industry, it has stepped into the field of precision medicine. Through this investment, we will complement each other's resources, expand the biotechnology and medical care business, and provide customers with a wider range of products and services. 16.Any dissenting opinions of directors to the present transaction:No 17.Whether the counterparty of the current transaction is a related party:No 18.Date of the board of directors resolution:NA 19.Date of ratification by supervisors or approval by the Audit Committee:NA 20.Whether the CPA issued an unreasonable opinion regarding the current transaction:No 21.Name of the CPA firm:WeTec International CPAs 22.Name of the CPA:Lai Ming-Yang 23.Practice certificate number of the CPA: Taipei City CPA Certificate No. 2123 24.Whether the transaction involved in change of business model:No 25.Details on change of business model:No 26.Details on transactions with the counterparty for the past year and the expected coming year:No 27.Source of funds:Self-owned capital 28.Any other matters that need to be specified: No |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Qisda Corporation published this content on 20 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 May 2022 08:24:09 UTC.